IMPORTANT SAFETY INFORMATION There are no contraindications forIMFINZI®(durvalumab)or IMJUDO®(tremelimumab-actl). Severe and Fatal Immune-Mediated Adverse Reactions Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatalimmune-mediate...
INO-3122 + durvalumab Plasmid vector-based vaccine + PDL1 inhibitor HPV related cancer Phase II(Active, not recruiting) NCT03439085 ProCervix with imiquimod Protein-based vaccine and TLR 7 agonist HPV16/18-related infections Phase II(Completed) NCT01957878 HSP-E7 Protein-based vaccine HPV16-related...
In addition, TCR repertoire measured in peripheral blood samples and tumor tissue may provide a useful tool for predicting the risk of recurrence after neoadjuvant durvalumab in patients with resectable stage IIIA(N2) NSCLC [55]. Furthermore, in patients with resect- able NSCLC who underwent ...
However, the reported survival advantage has been modest in subsequent trials, and many combinations with different drugs including checkpoint inhibitors (e.g., durvalumab) or targeted therapies (e.g., glasdegib, histone deacetylase inhibitors) have been tried without incremental improvements of outcomes...
Current clinical practice in advanced NSCLC is largely based on results from the phase 3 PACIFIC trial [95], which demonstrated the benefit of consolidation therapy with the PD-L1 inhibitor Durvalumab in patients who did not have disease progression after two or more cycles of chemo-radiotherapy....